Grid Therapeutics' Series B Round

Grid Therapeutics raised a round of funding on March 29, 2018.

Grid Therapeutics is a biotechnology company developing a human derived targeted immunotherapy which leverages a novel approach of identifying specific tumor immunoglobulin G (IgG) antibodies from pat…

Articles about Grid Therapeutics' Series B Round: